Trial Profile

A phase 1 trial of EVM-14

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 08 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EVM 14 (Primary)
Indications Cancer
Focus Adverse reactions

Most Recent Events

08 Apr 2025 New trial record
23 Mar 2025 According to an Everest Medicines media release, company submit the IND application for EVM14 to the China National Medical Products Administration (NMPA) in the near future.
23 Mar 2025 According to an Everest Medicines media release, company announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EVM14.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com